Protein c concentrate as adjuvant treatment in neonates with sepsis-induced coagulopathy: A pilot study

Lidia Decembrino, Armando D'Angelo, Franco Manzato, Agostina Solinas, Francesco Tumminelli, Annalisa De Silvestri, Sandro De Lazzari, Ezio Padovani, Mariella Magarotto, Lino Chiandetti, Sergio O. Saia, Mauro Stronati

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The objective of the study is to describe safety and effects of protein C concentrate (PCConc) administration in neonates with sepsis-induced coagulopathy. Eighteen neonates (12 preterm and 6 full term) aged between 1 and 28 days who have severe sepsis (n = 6) or septic shock (n = 12), with coagulopathy and acquired protein C (PC) deficiency received PCConc (i.v. bolus of 100 IU/kg, followed by 50 IU/kg every 6 h for 72 h). Platelet counts, prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, D-dimer, C-reactive protein (CRP), antithrombin (AT), PC, CRP, and neonatal therapeutic intervention scoring system (NTISS) were assessed before and 24, 48, and 72 h after the study entry. According to Clinical Risk Index for Babies II score (CRIB II score), the expected mortality in preterms was 10%. After 24 h of treatment, PC activity levels increased from an average of 19% to 57%, and they were within normal limits before the last PCConc bolus. During the treatment period, a shortening of PT (P = 0.04) and activated partial thromboplastin time (P = 0.02), and an increase in antithrombin levels (P <0.0001) were observed, along with a reduction in CRP (P = 0.005) and NTISS values (P = 0.003). No adverse events were observed. This pilot study shows that in neonatal severe sepsis, normalization of PC levels is safe and probably effective in modulating the inflammatory response and in controlling coagulopathy. However, for the potential beneficial effects of PCConc administration on morbidity and mortality, a placebo-controlled, double-blind study is required.

Original languageEnglish
Pages (from-to)341-345
Number of pages5
JournalShock
Volume34
Issue number4
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Protein C
Sepsis
Proteins
Partial Thromboplastin Time
Prothrombin Time
C-Reactive Protein
Antithrombin Proteins
Dilatation and Curettage
Antithrombins
Mortality
Therapeutics
Septic Shock
Platelet Count
Double-Blind Method
Fibrinogen
Placebos
Morbidity
Safety

Keywords

  • coagulopathy
  • Neonatal severe sepsis
  • protein C
  • protein C concentrate

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Emergency Medicine

Cite this

Protein c concentrate as adjuvant treatment in neonates with sepsis-induced coagulopathy : A pilot study. / Decembrino, Lidia; D'Angelo, Armando; Manzato, Franco; Solinas, Agostina; Tumminelli, Francesco; De Silvestri, Annalisa; De Lazzari, Sandro; Padovani, Ezio; Magarotto, Mariella; Chiandetti, Lino; Saia, Sergio O.; Stronati, Mauro.

In: Shock, Vol. 34, No. 4, 10.2010, p. 341-345.

Research output: Contribution to journalArticle

Decembrino, L, D'Angelo, A, Manzato, F, Solinas, A, Tumminelli, F, De Silvestri, A, De Lazzari, S, Padovani, E, Magarotto, M, Chiandetti, L, Saia, SO & Stronati, M 2010, 'Protein c concentrate as adjuvant treatment in neonates with sepsis-induced coagulopathy: A pilot study', Shock, vol. 34, no. 4, pp. 341-345. https://doi.org/10.1097/SHK.0b013e3181e7623e
Decembrino, Lidia ; D'Angelo, Armando ; Manzato, Franco ; Solinas, Agostina ; Tumminelli, Francesco ; De Silvestri, Annalisa ; De Lazzari, Sandro ; Padovani, Ezio ; Magarotto, Mariella ; Chiandetti, Lino ; Saia, Sergio O. ; Stronati, Mauro. / Protein c concentrate as adjuvant treatment in neonates with sepsis-induced coagulopathy : A pilot study. In: Shock. 2010 ; Vol. 34, No. 4. pp. 341-345.
@article{7eaeed4c69424599a5b05b9db780e547,
title = "Protein c concentrate as adjuvant treatment in neonates with sepsis-induced coagulopathy: A pilot study",
abstract = "The objective of the study is to describe safety and effects of protein C concentrate (PCConc) administration in neonates with sepsis-induced coagulopathy. Eighteen neonates (12 preterm and 6 full term) aged between 1 and 28 days who have severe sepsis (n = 6) or septic shock (n = 12), with coagulopathy and acquired protein C (PC) deficiency received PCConc (i.v. bolus of 100 IU/kg, followed by 50 IU/kg every 6 h for 72 h). Platelet counts, prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, D-dimer, C-reactive protein (CRP), antithrombin (AT), PC, CRP, and neonatal therapeutic intervention scoring system (NTISS) were assessed before and 24, 48, and 72 h after the study entry. According to Clinical Risk Index for Babies II score (CRIB II score), the expected mortality in preterms was 10{\%}. After 24 h of treatment, PC activity levels increased from an average of 19{\%} to 57{\%}, and they were within normal limits before the last PCConc bolus. During the treatment period, a shortening of PT (P = 0.04) and activated partial thromboplastin time (P = 0.02), and an increase in antithrombin levels (P <0.0001) were observed, along with a reduction in CRP (P = 0.005) and NTISS values (P = 0.003). No adverse events were observed. This pilot study shows that in neonatal severe sepsis, normalization of PC levels is safe and probably effective in modulating the inflammatory response and in controlling coagulopathy. However, for the potential beneficial effects of PCConc administration on morbidity and mortality, a placebo-controlled, double-blind study is required.",
keywords = "coagulopathy, Neonatal severe sepsis, protein C, protein C concentrate",
author = "Lidia Decembrino and Armando D'Angelo and Franco Manzato and Agostina Solinas and Francesco Tumminelli and {De Silvestri}, Annalisa and {De Lazzari}, Sandro and Ezio Padovani and Mariella Magarotto and Lino Chiandetti and Saia, {Sergio O.} and Mauro Stronati",
year = "2010",
month = "10",
doi = "10.1097/SHK.0b013e3181e7623e",
language = "English",
volume = "34",
pages = "341--345",
journal = "Shock",
issn = "1073-2322",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Protein c concentrate as adjuvant treatment in neonates with sepsis-induced coagulopathy

T2 - A pilot study

AU - Decembrino, Lidia

AU - D'Angelo, Armando

AU - Manzato, Franco

AU - Solinas, Agostina

AU - Tumminelli, Francesco

AU - De Silvestri, Annalisa

AU - De Lazzari, Sandro

AU - Padovani, Ezio

AU - Magarotto, Mariella

AU - Chiandetti, Lino

AU - Saia, Sergio O.

AU - Stronati, Mauro

PY - 2010/10

Y1 - 2010/10

N2 - The objective of the study is to describe safety and effects of protein C concentrate (PCConc) administration in neonates with sepsis-induced coagulopathy. Eighteen neonates (12 preterm and 6 full term) aged between 1 and 28 days who have severe sepsis (n = 6) or septic shock (n = 12), with coagulopathy and acquired protein C (PC) deficiency received PCConc (i.v. bolus of 100 IU/kg, followed by 50 IU/kg every 6 h for 72 h). Platelet counts, prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, D-dimer, C-reactive protein (CRP), antithrombin (AT), PC, CRP, and neonatal therapeutic intervention scoring system (NTISS) were assessed before and 24, 48, and 72 h after the study entry. According to Clinical Risk Index for Babies II score (CRIB II score), the expected mortality in preterms was 10%. After 24 h of treatment, PC activity levels increased from an average of 19% to 57%, and they were within normal limits before the last PCConc bolus. During the treatment period, a shortening of PT (P = 0.04) and activated partial thromboplastin time (P = 0.02), and an increase in antithrombin levels (P <0.0001) were observed, along with a reduction in CRP (P = 0.005) and NTISS values (P = 0.003). No adverse events were observed. This pilot study shows that in neonatal severe sepsis, normalization of PC levels is safe and probably effective in modulating the inflammatory response and in controlling coagulopathy. However, for the potential beneficial effects of PCConc administration on morbidity and mortality, a placebo-controlled, double-blind study is required.

AB - The objective of the study is to describe safety and effects of protein C concentrate (PCConc) administration in neonates with sepsis-induced coagulopathy. Eighteen neonates (12 preterm and 6 full term) aged between 1 and 28 days who have severe sepsis (n = 6) or septic shock (n = 12), with coagulopathy and acquired protein C (PC) deficiency received PCConc (i.v. bolus of 100 IU/kg, followed by 50 IU/kg every 6 h for 72 h). Platelet counts, prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, D-dimer, C-reactive protein (CRP), antithrombin (AT), PC, CRP, and neonatal therapeutic intervention scoring system (NTISS) were assessed before and 24, 48, and 72 h after the study entry. According to Clinical Risk Index for Babies II score (CRIB II score), the expected mortality in preterms was 10%. After 24 h of treatment, PC activity levels increased from an average of 19% to 57%, and they were within normal limits before the last PCConc bolus. During the treatment period, a shortening of PT (P = 0.04) and activated partial thromboplastin time (P = 0.02), and an increase in antithrombin levels (P <0.0001) were observed, along with a reduction in CRP (P = 0.005) and NTISS values (P = 0.003). No adverse events were observed. This pilot study shows that in neonatal severe sepsis, normalization of PC levels is safe and probably effective in modulating the inflammatory response and in controlling coagulopathy. However, for the potential beneficial effects of PCConc administration on morbidity and mortality, a placebo-controlled, double-blind study is required.

KW - coagulopathy

KW - Neonatal severe sepsis

KW - protein C

KW - protein C concentrate

UR - http://www.scopus.com/inward/record.url?scp=77957707995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957707995&partnerID=8YFLogxK

U2 - 10.1097/SHK.0b013e3181e7623e

DO - 10.1097/SHK.0b013e3181e7623e

M3 - Article

C2 - 20823695

AN - SCOPUS:77957707995

VL - 34

SP - 341

EP - 345

JO - Shock

JF - Shock

SN - 1073-2322

IS - 4

ER -